| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/31/2005 | US6899896 Hydrogel-driven layered drug dosage form |
| 05/31/2005 | US6899867 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 05/31/2005 | CA2332929C Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles |
| 05/31/2005 | CA2267157C Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
| 05/26/2005 | WO2005028438A9 Novel piperidine derivative |
| 05/26/2005 | WO2005014001A9 Use of 2h- [1, 3] - oxazino [3, 2-a] indole derivatives for the treatment of neuropathic pain |
| 05/26/2005 | WO2005007642A3 Novel azaheterocyclic amides useful for treating pain |
| 05/26/2005 | WO2005000843A3 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 05/26/2005 | WO2004046136A9 Pyrazine compounds as crf modulators |
| 05/26/2005 | US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases |
| 05/26/2005 | US20050113451 7-acetamidinyl derivatives |
| 05/26/2005 | US20050113430 2-[o-(aminoalkoxy)phenyl])-3-acylbenzothiazolines, e.g., 3-Acetyl-6-chloro-2-[2-(3-(N-(2-hydroxyethyl)-N-isopropylamino)-propoxy)-5-methoxyphenyl]benzothiazoline; treating pruritus or pain, particularly that caused by a rheumatic disease |
| 05/26/2005 | US20050113416 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 05/26/2005 | US20050113414 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens |
| 05/26/2005 | US20050113386 Treating bipolar disorder, mania, dementia, sexual dysfunction, eating disorders, fibromyalgia |
| 05/26/2005 | US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep |
| 05/26/2005 | US20050113380 [1,2,4]-Triazole bicyclic adenosine A2a receptor antagonists |
| 05/26/2005 | US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors |
| 05/26/2005 | US20050113370 Therapeutic substituted indazole derivatives |
| 05/26/2005 | US20050113368 eg (+-) Ethyl 3-[4-{3-(3,4-dihydro-2H-benzo[b][1,4]oxazin-4-yl)propylamino}phenyl]-2-ethoxypropanoate; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic |
| 05/26/2005 | US20050113366 Derivatives of 4-hydroxybutanoic acid and of its higher homologue as ligands of $g(g)-hydroxybutyrate (ghb) receptors, pharmaceutical compositions containing same and pharmaceutical uses |
| 05/26/2005 | US20050113361 Amide derivatives as NMDA receptor antagonists |
| 05/26/2005 | US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one |
| 05/26/2005 | US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone |
| 05/26/2005 | US20050113357 Cholinergic agents such as 3-[3-(4-methoxypiperidine)-1-yl-propyl]-1H-indole; for therapy of cognitive dysfunction, forgetfulness, confusion, memory loss, attention deficits, deficits in visual perception, depression, pain, sleep disorders, and psychosis |
| 05/26/2005 | US20050113322 Oligonucleotides which hybridize to inhibit expression; nucleosides; chimera; colloids; cardiovascular disorders; nervous system disorders; diabetes; ischemia/reperfusion injuries |
| 05/26/2005 | US20050113310 Use of inhibitors of enzymes having activities of amino peptidase N and/or dipeptidyl peptidase IV and of pharmaceutical preparations thereof for a therapy and prevention of chronical neurodegenerative diseases |
| 05/26/2005 | US20050113299 Protein a compositions and methods of use |
| 05/26/2005 | US20050113284 Drug for regenerating tissue and vessel and method therefor |
| 05/26/2005 | US20050112748 Low molecular weight gtpase rhot |
| 05/26/2005 | US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 05/26/2005 | US20050112575 Nucleic acid sequence encoding polypeptides; triggering calcium oscillation in ooctyes ; determination fertility |
| 05/26/2005 | US20050112565 Proteases |
| 05/26/2005 | US20050112206 Mixture of drug, aminoacrylate polymer and acid |
| 05/26/2005 | US20050112197 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics |
| 05/26/2005 | US20050112146 Administering neurotoxin to infants; cerebral palsy therapy |
| 05/26/2005 | US20050112127 Treating with active material having heavy chain variable region of amino acid sequence 7 and light chain variable region of sequence 8; psoriasis, multiple sclerosis, Crohn's disease |
| 05/26/2005 | US20050112126 Anti-VEGF antibodies |
| 05/26/2005 | CA2547474A1 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter |
| 05/26/2005 | CA2545731A1 Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders |
| 05/26/2005 | CA2545373A1 Novel 1,3-disubstituted azetidine derivatives for use as 5ht2a receptor ligands |
| 05/26/2005 | CA2545364A1 Methods of modulating angiogenesis and cancer cell proliferation |
| 05/26/2005 | CA2545254A1 Substituted triazoles as sodium channel blockers |
| 05/26/2005 | CA2545190A1 Agent for preventing and treating language disorders |
| 05/26/2005 | CA2545060A1 Methods of use of thrombin receptor antagonists |
| 05/26/2005 | CA2544252A1 Stem cell culture medium and method of using said medium and the cells |
| 05/26/2005 | CA2544245A1 Use of selective opiate receptor modulators in the treatment of neuropathy |
| 05/26/2005 | CA2543627A1 Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands |
| 05/25/2005 | EP1533374A1 Novel peptides having camp producing activity |
| 05/25/2005 | EP1533312A1 Hetero-bicyclic compounds |
| 05/25/2005 | EP1533299A1 Indole derivatives and drugs containing the same |
| 05/25/2005 | EP1533294A1 Beta-alanine derivative and use thereof |
| 05/25/2005 | EP1532987A1 Agents for gene therapeutic for cerebrovascular disorders |
| 05/25/2005 | EP1532446A2 G-protein coupled receptor ligands and methods |
| 05/25/2005 | EP1532276A2 Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases |
| 05/25/2005 | EP1532251A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use |
| 05/25/2005 | EP1532242A2 Methods for preparing purified prostaglandin e synthase |
| 05/25/2005 | EP1532238A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 05/25/2005 | EP1532170A2 Beta-sheet breaking peptides |
| 05/25/2005 | EP1532161A2 Vectors for expression of hml-2 polypeptides |
| 05/25/2005 | EP1532155A2 C6- AND C9-SUBSTITUTED CHROMENO[4,3-c]ISOXAZOLINE DERIVATIVES AND THEIR USE AS ANTI-DEPRESSANTS |
| 05/25/2005 | EP1532152A1 Novel polymorph of n-methyl-n-(3- 3- 2-thienylcarbonyl]-pyrazol- 1,5-alpha]-pyrimidin-7-yl phenyl)acetamide and compositions and methods related thereto |
| 05/25/2005 | EP1532148A1 Novel purine- or pyrrolol(2,3-d)pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity |
| 05/25/2005 | EP1532147A1 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 05/25/2005 | EP1532145A1 Pyrazole compositions useful as inhibitors of gsk-3 |
| 05/25/2005 | EP1532144A1 Novel quinuclidine derivatives and their use |
| 05/25/2005 | EP1532141A1 2-pyrrolidin-2-yl- 1,3,4]-oxadiazole derivatives and the use of the same as antidepressants |
| 05/25/2005 | EP1532135A1 Nf-kb inhibitors |
| 05/25/2005 | EP1532133A1 Nf-:b inhibitors |
| 05/25/2005 | EP1532124A1 Novel compounds |
| 05/25/2005 | EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| 05/25/2005 | EP1532121A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives |
| 05/25/2005 | EP1532105A1 Anthranyl derivatives having an anticholecystokinin activity (anti-cck-1), a process for their preparation, and pharmaceutical use thereof |
| 05/25/2005 | EP1532104A1 Crystalline beta-2 adrenergic receptor agonist |
| 05/25/2005 | EP1531905A1 Metallothionein based neuronal therapeutic and therapeutic methods |
| 05/25/2005 | EP1531867A1 Metastable pharmaceutical compositions |
| 05/25/2005 | EP1531844A2 Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 05/25/2005 | EP1531837A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions |
| 05/25/2005 | EP1531820A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases |
| 05/25/2005 | EP1531817A1 Glycinamide derivatives as raf-kinase inhibitors |
| 05/25/2005 | EP1531814A1 Sustained-release tablet composition of pramipexole |
| 05/25/2005 | EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 05/25/2005 | EP1531808A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions |
| 05/25/2005 | EP1531807A1 Bazedoxifene treatment regimens |
| 05/25/2005 | EP1531799A1 Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions |
| 05/25/2005 | EP1531798A2 Pulmonary delivery for levodopa |
| 05/25/2005 | EP1451189B1 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo- 3.2.2]nonane derivatives, preparation and therapeutic use thereof |
| 05/25/2005 | EP1341791B1 Thioether substituted imidazoquinolines |
| 05/25/2005 | EP1287137B1 REGULATION OF HUMAN $g(a)1A?ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR |
| 05/25/2005 | EP1163335B1 MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION |
| 05/25/2005 | EP1056724B1 Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands |
| 05/25/2005 | EP1044023B1 A covalent conjugate of clozapine with a fatty acid and its use for treating schizophrenia |
| 05/25/2005 | EP0994903B1 Methods and compositions for galactosylated glycoproteins |
| 05/25/2005 | EP0946511B1 Novel compounds with analgesic effect |
| 05/25/2005 | EP0836613B1 Water-soluble adenosine kinase inhibitors |
| 05/25/2005 | EP0813416B1 Reduction of infarct volume using citicoline |
| 05/25/2005 | DE10359336A1 Use of potassium channel openers in synergistic combination with sodium channel inhibiting/influencing active compounds for treating pains accompanied by increase in muscle tone |
| 05/25/2005 | DE10359335A1 Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen Combinations of potassium channel openers and sodium channel inhibitors and sodium channel influencing agents for the treatment of pain |
| 05/25/2005 | CN1620510A Cytokine protein family |
| 05/25/2005 | CN1620467A Secreted protein |